Opinion|Videos|May 16, 2025
CD4 T-cell and Lymphocyte Monitoring: Clinical Significance in HIV Treatment
Author(s)Sharon Walmsley, CM, MD, FRCPC
A panelist discusses how CD4 counts serve as measures of immune system status that typically increase by about 200 in the first year of antiretroviral therapy. Although there can be laboratory variability, these counts remain important for patient monitoring and identifying those at risk for complications.
Advertisement
CD4 T-Cell Monitoring in HIV Management
Key Themes:
- Immune Reconstitution: Average CD4 count increases of approximately 200 cells in the first year of effective therapy
- Laboratory Variability: CD4 count fluctuations of up to 20% between measurements, causing potential patient concern
- Clinical Utility Debate: Discussion of whether routine CD4 monitoring remains necessary in stable patients
- Toxicity Monitoring: Importance of CD4 count monitoring in trials of new agents with potential lymphotoxicity
Notable Insights from Dr Sharon Walmsley:
- Despite some recommendations to reduce CD4 monitoring (“choosing wisely” initiatives), many patients value these numbers as reinforcement that treatment is working.
- CD4 counts remain important for guiding opportunistic infection prophylaxis decisions in patients with lower values.
- CD4 monitoring can serve as a motivational tool for patients struggling with adherence.
- In switch studies, CD4 counts typically remain stable when patients are already virologically suppressed.
Advertisement
Related to this article
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
3
GLP-1 Receptor Agonists Cut Ascites, Mortality in MASH
4
Hepatitis A Vaccine Prevents 96% of Infections Given Before Exposure
5